請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20716
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊泮池,陳璿宇 | |
dc.contributor.author | Ting-Chun Kuo | en |
dc.contributor.author | 郭廷群 | zh_TW |
dc.date.accessioned | 2021-06-08T03:00:05Z | - |
dc.date.copyright | 2017-09-08 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-07-26 | |
dc.identifier.citation | References
1. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136(5), E359-386. 2. Chiang, C. J.; Lo, W. C.; Yang, Y. W.; et al. Incidence and survival of adult cancer patients in Taiwan, 2002-2012. J. Formos. Med. Assoc. 2016, 115(12), 1076-1088. 3. 103 年各類癌症健保前 10 大醫療支出統計. Retrieved June 28, 2017, from http://www.nhi.gov.tw/News_Content.aspx?n=FC05EB85BD57C709&sms=587F1A3D9A03E2AD&s=B164A72522D27089. 4. Non-Small Cell Lung Cancer - American Cancer Society. Retrieved June 28, 2017, from https://www.cancer.org/cancer/non-small-cell-lung-cancer.html. 5. Ellis, P. M.; Vandermeer, R. Delays in the diagnosis of lung cancer. J. Thorac. Dis. 2011, 3(3), 183-188. 6. NCCN clinical practice guidelines in oncology for treatment of non-small cell lung cancer. Version 6.2017. 7. Whitson, B. A.; Groth, S. S.; Duval, S. J.; et al. Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann. Thorac. Surg. 2008, 86(6), 2008-2016. 8. Baker, S.; Dahele, M.; Lagerwaard, F. J.; et al. A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiat. Oncol. 2016, 11(1), 115. 9. Bareschino, M. A.; Schettino, C.; Rossi, A.; et al. Treatment of Advanced non small cell lung cancer. J. Thorac. Dis. 2011, 3(2), 122-133. 10. Du, L.; Morgensztern, D. Chemotherapy for Advanced-Stage Non-Small Cell Lung Cancer. Cancer J. 2015, 21(5), 366-370. 11. Levy, B.; Saxena, A.; Schneider, B. J.; et al. Systemic therapy for small cell lung cancer. J. Natl. Compr. Canc. Netw. 2013, 11(7), 780-787. 12. Einhorn, L. H. First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? J. Clin. Oncol. 2008, 26(21), 3485-3486. 13. Sederholm, C.; Gillerdal, G.; Lamberg, K; et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non–small-cell lung cancer: The Swedish Lung Cancer Study Group. J. Clin. Oncol. 2005, 23(33), 8380-8388. 14. Scagliotti, G. V.; Parikh, P.; von Pawel, J.; et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage NSCLC. J. Clin. Oncol. 2008, 26(21), 3543-3551. 15. Tomasini, P.; Barlesi, F.; Mascaux, C.; et al. Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes. Ther. Adv. Med. Oncol. 2016, 8(3), 198-208. 16. Otake, Y.; Tanaka, F.; Yanagihara, K.; et al. Expression of thymidylate synthase in human non-small cell lung cancer. Jpn. J. Cancer Res. 1999, 90(11), 1248–1253. 17. Forde, P. M.; Ettinger, D. S. Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev. Anticancer Ther. 2013, 13(6), 745-758. 18. Shi, Y.; Li, J.; Zhang, S.; et al. Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. PLoS One 2015, 10(11), e0143515. 19. Gazdar, A. F. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009, 28(Suppl 1), S24-S31. 20. Chia, P. L.; Mitchell, P.; Dobrovic, A.; et al. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin. Epidemiol. 2014, 6, 423-432. 21. Awad, M. M.; Shaw, A. T. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin. Adv. Hematol. Oncol. 2014, 12(7), 429-439. 22. Shaw, A. T.; Ou, S. H.; Bang, Y. J.; et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 2014, 371(21), 1963-1971. 23. Munhoz, R. R.; Postow, M. A. Recent advances in understanding antitumor immunity. F1000Res. 2016, 5, 2545. 24. Sgambato, A.; Casaluce, F.; Sacco, P. C.; et al. Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management. Curr. Drug Saf. 2016, 11(1), 62-68. 25. Mino-Kenudson, M. Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? Cancer Biol. Med. 2016, 13(2), 157-170. 26. Stewart, E. L.; Tan, S. Z.; Liu, G.; et al. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl. Lung Cancer Res. 2015, 4(1), 67-81. 27. Neel, D. S.; Bivona, T. G. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. npj Precision Oncology 2017, 1, 3. 28. Bianco, R.; Damiano, V.; Gelardi, T.; et al. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. Curr. Pharm. Des. 2007, 13(33), 3358-3367. 29. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 2011, 144(5), 646-674. 30. Sonnenschein, C.; Soto, A. M. The aging of the 2000 and 2011 Hallmarks of Cancer reviews: a critique. J. Biosci. 2013, 38(3), 651-663. 31. Rosa, R.; Monteleone, F.; Zambrano, N.; et al. In vitro and in vivo models for analysis of resistance to anticancer molecular therapies. Curr. Med. Chem. 2014, 21(14), 1595-1606. 32. Rakoff-Nahoum S. Why cancer and inflammation? Yale J. Biol. Med. 2006, 79(3-4), 123-130. 33. Casás-Selves, M.; Degregori, J. How cancer shapes evolution, and how evolution shapes cancer. Evolution (N Y) 2011, 4(4), 624-634. 34. Warburg, O.; Posener, K.; Negelein, E. Ueber den stoffwechsel der tumoren. Biochem Z. 1924, 152: 319-344. 35. Devic, S. Warburg Effect - a Consequence or the Cause of Carcinogenesis? J. Cancer 2016, 7(7), 817-822. 36. Vernieri, C.; Casola, S.; Foiani, M.; et al. Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. Cancer Discov. 2016, 6(12), 1315-1333. 37. Jinushi M. Yin and yang of tumor inflammation: how innate immune suppressors shape the tumor microenvironments. Int. J. Cancer 2014, 135(6), 1277-1285. 38. Azoury, S. C.; Straughan, D. M.; Shukla, V. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety. Curr. Cancer Drug Targets 2015, 15(6), 452-462. 39. Higa, G. M. The microtubule as a breast cancer target. Breast Cancer 2011, 18, 103–119. 40. Stanton, R. A.; Gernert, K. M.; Nettles, J. H.; Aneja R. Drugs that target dynamic microtubules: a new molecular perspective. Med. Res. Rev. 2011, 31, 443–481. 41. Dumontet, C.; Jordan, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 2010, 9(10), 790-803. 42. Gan, P. P.; McCarroll, J. A.; Po'uha, S. T.; et al. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol. Cancer Ther. 2010, 9(5), 1339-1348. 43. Allan, L. A.; Clarke, P. R. Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol Cell 2007, 26(2), 301-310. 44. Terrano, D. T.; Upreti, M.; Chambers, T. C. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol. Cell Biol. 2010, 30(3), 640-656. 45. Wertz, I. E.; Kusam, S.; Lam, C.; et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011, 471(7336), 110-114. 46. Etienne-Manneville, S. From signaling pathways to microtubule dynamics: the key players. Curr. Opin. Cell. Biol. 2010, 22, 104–111. 47. Van der Vaart, B.; Akhmanova, A.; Straube, A. Regulation of microtubule dynamic instability. Biochem. Soc. Trans. 2009, 37, 1007–1013. 48. Rovini, A.; Savry, A.; Braguer, D.; Carré, M. Microtubule-targeted agents: when mitochondria become essential to chemotherapy. Biochem. Biophys. Acta. 2011, 1807, 679–688. 49. Katsetos, C. D.; Dráber, P. Tubulins as therapeutic targets in cancer: from bench to bedside. Curr. Pharm. Des. 2012, 18, 2778–2792. 50. Perez, E. A. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol. Cancer. Ther. 2009, 8, 2086–2095. 51. Ganguly, A.; Cabral, F. New insights into mechanisms of resistance to microtubule inhibitors. Biochim. Biophys. Acta. 2011, 1816(2), 164-171. 52. Yang, J.; Yu ,Y.; Liu, W.; et al. Microtubule-associated protein tau is associated with the resistance to docetaxel in prostate cancer cell lines. Res. Rep. Urol. 2017, 9, 71-77. 53. Bhat, K. M.; Setaluri, V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin. Cancer Res. 2007, 13, 2849–2854. 54. Miceli, C.; Tejada, A.; Castaneda, A.; et al. Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer. Cancer Gene Ther. 2013, 20, 298-307. 55. Rouzier, R.; Rajan, R.; Wagner, P.; et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 8315-8320. 56. Sharp, D. J.; Ross, J. L. Microtubule-severing enzymes at the cutting edge. J. Cell Sci. 2012, 125, 2561–2569. 57. Baas, P. W.; Sharma, V. Cell migration: katanin gives microtubules a trim. Curr. Biol. 2011, 21, 302–304. 58. Ghosh, D. K.; Dasgupta, D.; Guha, A. Models, Regulations, and Functions of Microtubule Severing by Katanin. ISRN Molecular Biology 2012, 2012, 1–14. 59. Ye, X.; Lee, Y. C.; Choueiri, M.; et al. Aberrant expression of katanin p60 in prostate cancer bone metastasis. Prostate 2012, 72, 291–300. 60. Sudo, H.; Maru, Y. LAPSER1 is a putative cytokinetic tumor suppressor that shows the same centrosome and midbody subcellular localization pattern as p80 katanin. FASEB J. 2007, 21, 2086–2100. 61. Macarron, R.; Banks, M. N.; Bojanic, D.; et al. Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discov. 2011, 10(3), 188-195. 62. Yeh, C. T.; Wu, A. T.; Chang, P. M.; et al. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am. J. Respir. Crit. Care. Med. 2012, 186, 1180 –1188. 63. Chu, Y. W.; Yang, P. C.; Yang, S. C.; et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am. J. Respir. Cell Mol. Biol. 1997, 17, 353–360. 64. Liu, Y. M.; Chen, H. L.; Lee, H. Y.; et al. Tubulin inhibitors: a patent review. Expert Opin. Ther. Pat. 2014, 24, 69–88. 65. Mukhtar, E.; Adhami, V. M.; Mukhtar, H. Targeting microtubules by natural agents for cancer therapy. Mol. Cancer Ther. 2014, 13(2), 275-284. 66. Leslie, E. M.; Deeley, R. G.; Cole, S. P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 2005, 204(3), 216-237. 67. Callaghan, R.; Luk, F.; Bebawy, M. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab. Dispos. 2014, 42(4), 623-631. 68. Stengel, C.; Newman, S. P.; Leese, M. P. Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br. J. Cancer 2010, 102(2), 316-324. 69. Gan, P. P.; Kavallaris, M. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity. Cancer Res. 2008, 68(23), 9817-9824. 70. Maccioni, R. B.; Cambiazo, V. Role of microtubule-associated proteins in the control of microtubule assembly. Physiol. Rev. 1995, 75(4), 835-864. 71. Chin, G. M.; Herbst, R. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Mol. Cancer Ther. 2006, 5(10), 2580-2591. 72. Marcus, A. I.; Peters, U.; Thomas, S. L.; et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J. Biol. Chem. 2005, 280(12), 11569-11577. 73. Roll-Mecak, A.; McNally, F. J. Microtubule-severing enzymes. Curr. Opin. Cell Biol. 2010, 22, 96–103. 74. Ahmad, F. J.; Yu, W.; McNally, F. J.; et al. An essential role for katanin in severing microtubules in the neuron. J. Cell Biol. 1999, 145, 305–315. 75. Sudo, H.; Baas, P. W. Acetylation of microtubules influences their sensitivity to severing by katanin in neurons and fibroblasts. J. Neurosci. 2010, 30, 7215–7226. 76. Shiina, N.; Gotoh, Y.; Nishida, E. Microtubule-severing activity in M phase. Trends Cell Biol. 1995, 5, 283–286. 77. McNally, K.; Audhya, A.; Oegema, K.; et al. Katanin controls mitotic and meiotic spindle length. J. Cell Biol. 2006, 175, 881–891. 78. Maddika, S.; Chen, J. Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase. Nat. Cell Biol. 2009, 11, 409–419. 79. Toyo-Oka, K.; Sasaki, S.; Yano, Y.; et al. Recruitment of katanin p60 by phosphorylated NDEL1, an LIS1 interacting protein, is essential for mitotic cell division and neuronal migration. Hum. Mol. Genet. 2005, 14, 3113–3128. 80. Toyo-oka, K.; Mori, D.; Yano, Y.; et al. Protein phosphatase 4 catalytic subunit regulates Cdk1 activity and microtubule organization via NDEL1 dephosphorylation. J. Cell Biol. 2008, 180, 1133–1147. 81. Rhind, N.; Russell, P. Signaling pathways that regulate cell division. Cold Spring Harb. Perspect Biol. 2012, 4(10). 82. Xi, Q.; Huang, M.; Wang, Y.; et al. The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer. Tumour Biol. 2015, 36(7), 4939-4948. 83. Singhal, S.; Amin, K. M.; Kruklitis, R.; et al. Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling. Cancer Biol. Ther. 2003, 2, 291–298. 84. Zhang, C.; Elkahloun, A. G.; Robertson, M.; et al. Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance. PLoS One 2011, 6(8), e23849. 85. Sharma, D.; Soni, M.; Kumar, S.; et al. Solubility enhancement—eminent role in poorly soluble drugs. Research Journal of Pharmacy and Technology 2009, 2(2), 220–224. 86. Savjani, K. T.; Gajjar, A. K.; Savjani, J. K. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012,195727. 87. Kumar, A.; Sahoo, S. K.; Padhee, K.; et al. Review on solubility enhancement techniques for hydrophobic drugs. Pharmacie Globale 2011, 3(3), 001–007. 88. Docherty, R.; Pencheva, K.; Abramov, Y. A. Low solubility in drug development: de-convoluting the relative importance of solvation and crystal packing. J. Pharm. Pharmacol. 2015, 67(6), 847-856. 89. Vander Heiden, M. G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discovery 2011, 10(9), 671-684. 90. Phan, L. M.; Yeung, S. C.; Lee, M. H. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol. Med. 2014, 11(1), 1-19. 91. Granchi, C.; Fancelli, D.; Minutolo, F. An update on therapeutic opportunities offered by cancer glycolytic metabolism. Bioorg Med. Chem. Lett. 2014, 24(21), 4915-4925. 92. Renner, K.; Singer, K.; Koehl, G. E.; et al. Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment. Front Immunol. 2017, 8, 248. 93. Liberti, M. V.; Locasale, J. W. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem. Sci. 2016, 41(3), 211-218. 94. Zhang, S.; Yang, C.; Yang, Z.; et al. Homeostasis of redox status derived from glucose metabolic pathway could be the key to understanding the Warburg effect. Am. J. Cancer Res. 2015, 5(3), 928-944. 95. Hadad, S.; Iwamoto, T.; Jordan, L.; et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res. Treat 2011, 128(3), 783-794. 96. Margel, D.; Urbach, D. R.; Lipscombe, L. L.; et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J. Clin. Oncol. 2013, 31(25):3069-3075. 97. Wink, K. C.; Belderbos, J. S.; Dieleman, E. M.; et al. Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy. Radiother Oncol. 2016, 118(3), 453-459. 98. Doherty, J. R.; Cleveland, J. L. Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 2013, 123(9), 3685-3692. 99. Holm, E.; Hagmuller, E.; Staedt, U.; et al. Substrate balances across colonic carcinomas in humans. Cancer Res. 1995, 55, 1373–1378. 100. Hirschhaeuser, F.; Sattler, U. G.; Mueller-Klieser, W. Lactate: a metabolic key player in cancer. Cancer Res. 2011, 71(22), 6921-6925. 101. Pösö, A. R. Monocarboxylate transporters and lactate metabolism in equine athletes: a review. Acta Vet Scand. 2002, 43(2), 63-74. 102. Iwanaga, T.; Kishimoto, A. Cellular distributions of monocarboxylate transporters: a review. Biomed. Res. 2015, 36(5), 279-301. 103. Halestrap, A. P. The monocarboxylate transporter family--Structure and functional characterization. IUBMB Life 2012, 64(1), 1-9. 104. Pértega-Gomes, N.; Vizcaíno, J. R.; Miranda-Gonçalves, V.; et al. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer 2011, 11, 312. 105. Doyen, J.; Trastour, C.; Ettore, F.; et al. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. Biochem. Biophys. Res. Commun. 2014, 415(1), 54-61. 106. Gao, H. J.; Zhao, M. C.; Zhang, Y. J.; et al. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration. J. Cancer Res. Clin. Oncol. 2015, 141(7), 1151-1162. 107. Boidot, R.; Végran, F.; Meulle, A.; et al. Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Res. 2012, 72(4), 939-948. 108. Kirk, P.; Wilson, M. C.; Heddle, C.; et al. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 2000, 19(15), 3896-3904. 109. Ullah, M. S.; Davies, A. J.; Halestrap, A. P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J. Biol. Chem. 2006, 281(14), 9030-9037. 110. Baenke, F.; Dubuis, S.; Brault, C.; et al. Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival. J. Pathol. 2015, 237(2), 152-165. 111. Chu, Y. W.; Yang, P. C.; Yang, S. C.; et al. Selection of invasive and metastatic subpopulations from a human lungadenocarcinoma cell line. Am. J. Respir. Cell Mol. Biol. 1997, 17(3):353–360. 112. Gyorffy, B.; Surowiak, P.; Budczies, J.; et al. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013, 8(12):e82241. 113. Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma; Shedden, K.; Taylor, J. M.; et al. Gene Expression-Based Survival Prediction in Lung Adenocarcinoma: A Multi-Site, Blinded Validation Study. Nat. Med. 2008, 14(8), 822-827. 114. Wu, G.; Nomoto, S.; Hoque, M. O.; et al. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res. 2003, 63(10), 2351–2357. 115. Collins, F. S.; Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 2015, 372(9), 793-795. 116. Vargas, A. J.; Harris, C. C. Biomarker development in the precision medicine era: lung cancer as a case study. Nat. Rev. Cancer 2016, 16(8), 525-537. 117. Friedman, A. A.; Letai, A.; Fisher, D. E.; et al. Precision medicine for cancer with next-generation functional diagnostics. Nat. Rev. Cancer 2015, 15(12), 747-756. 118. Pavlova, N. N.; Thompson, C. B. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016, 23(1), 27-47. 119. Cairns, R. A.; Harris, I. S.; Mak, T. W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11(2), 85-95. 120. Daemen, A.; Peterson, D.; Sahu, N.; et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2015, 112(32), E4410-E4417. 121. Baek, G.; Tse, Y. F.; Hu, Z.; et al. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Rep. 2014, 9(6), 2233-2249. 122. Jamali, S.; Klier, M.; Ames, S.; et al. Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function. Sci. Rep. 2015, 5, 13605. 123. Donovan, K.; Alekseev, O.; Qi, X.; et al. O-GlcNAc modification of transcription factor Sp1 mediates hyperglycemia-induced VEGF-A upregulation in retinal cells. Invest. Ophthalmol. Visual Sci. 2014, 55(12), 7862-7873. 124. Su, X.; Gi, Y. J.; Chakravarti, D.; et al. TAp63 is a master transcriptional regulator of lipid and glucose metabolism. Cell Metab. 2012, 16(4), 511-525. 125. D'Aguanno, S.; Barcaroli, D.; Rossi, C.; et al. P63 isoforms regulate metabolism of cancer stem cells. J. Proteome Res. 2014, 13(4), 2120-2136. 126. Lee, J. Y.; Lee, I.; Chang, W. J.; et al. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. Oncotarget 2016, 7(28), 43492-43503. 127. Pertega-Gomes, N.; Felisbino, S.; Massie, C. E.; et al. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. J. Pathol. 2015, 236(4), 517-530. 128. Warburg O. On the origin of cancer cells. Science 1956, 123(3191):309-314. 129. Ovens, M. J.; Davies, A. J.; Wilson, M. C.; et al. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem. J. 2010, 425(3), 523-530. 130. Le Floch, R.; Chiche, J.; Marchiq, I.; et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(40), 16663-16668. 131. Polański, R.; Hodgkinson, C. L.; Fusi, A.; et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin. Cancer Res. 2014, 20(4), 926-937. 132. Bola, B. M.; Chadwick, A. L.; Michopoulos, F.; et al. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol. Cancer Ther. 2014, 13(12), 2805-2816. 133. Halestrap, A. P. The SLC16 gene family - structure, role and regulation in health and disease. Mol. Aspects Med. 2013, 34(2-3):337-349. 134. Ibtissam, M.; Jacques, P. Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H+ symporters. J. Mol. Med. 2016, 94, 155–171. 135. Choi, S. Y.; Xue, H.; Wu, R.; et al. The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer. Clin. Cancer Res. 2016, 22(11), 2721-2733. 136. Kong, S. C.; Nøhr-Nielsen, A.; Zeeberg, K.; et al. Monocarboxylate Transporters MCT1 and MCT4 Regulate Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells. Pancreas 2016, 45(7), 1036-1047. 137. Dobroff, A. S.; Rodrigues, E. G.; Juliano, M. A.; et al. Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells. Transl. Oncol. 2010, 3(4), 204-217. 138. Díaz-Zaragoza, M.; Hernández-Ávila, R.; Viedma-Rodríguez, R.; et al. Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (Review). Oncol. Rep. 2015, 34(3), 1106-1114. 139. Cheong, T. C.; Compagno, M.; Chiarle, R.; et al. Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system. Nat. Commun. 2016, 7, 10934. 140. Cerutti, A.; Zan, H.; Schaffer, A.; CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+IgD+ B cell line. J. Immunol. 1998, 160(5), 2145-2157. 141. Maione, P.; Sacco, P. C.; Sgambato, A.; et al. Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application. Ther. Adv. Med. Oncol. 2015, 7(5), 263-273. 142. Russo, A.; Franchina, T.; Ricciardi, G. R.; et al. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget 2015, 6, 26814–26825. 143. Porporato, P. E.; Dhup, S.; Dadhich, R. K.; et al. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol. 2011, 2, 49. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20716 | - |
dc.description.abstract | 肺癌至今仍然是全世界致死率最高的癌症之一。儘管藥物或是手術方面於近年皆有長足的進步,但在有效降低肺癌致死率的部分仍不盡理想。歸納造成抗癌藥物無法展現有效的抗癌效果及提供安全的藥物劑量之眾多原因可發現,大多與癌症細胞快速產生抗藥性及抗癌藥物對人體正常細胞產生嚴重的副作用有關。但近年來隨著精準醫學此一觀念在抗癌藥物研究領域之蓬勃發展,越來越多的肺癌診斷標記蛋白及藥物標的在肺癌細胞中被發現,也再次為此領域注入了新的希望與發展方向。
於此博士論文中,我們運用了隨機藥物篩選及機制導向藥物設計兩種策略成功的找到了兩個可做為肺癌藥物標的之蛋白,katanin蛋白及Monocarboxylate transporter 4 (MCT4)蛋白。同時我們亦針對其分別發展出能有效抑制肺癌細胞生長之抗癌藥物,GRC0321及MCT4中和抗體。此兩藥物不論是在細胞內或是動物體內之實驗模型中都展現了良好的抗癌效果及優異的安全性。在詳細的藥物抗癌機轉研究中,我們發現小分子藥物GRC0321是透過影響katanin蛋白來破壞癌症細胞微管的完整性。而後,此一現象將會進一步地造成癌症細胞G2/M細胞週期停滯,並導致癌症細胞走向由caspase-9 蛋白所主導的細胞凋亡途徑。關於MCT4中和抗體造成糖解作用依賴型肺癌細胞生長停滯的機轉部分,我們則發現此一抗體能有效的抑制癌症細胞將堆積於細胞內之多餘乳酸運送到細胞外之機制。此一抑制機制可以進一步的造成癌症細胞細胞內之pH值降低,並同時產生過量之活性氧化物質。而最後則一樣會造成癌症細胞走向由caspase-9 蛋白所主導的細胞凋亡途徑。此外,我們亦發現MCT4中和抗體在MCT4大量表性之肺癌細胞中能展現較好之抗癌能力。詳細研究後發現,因為此類肺癌細胞較依賴糖解作用來得到能量,且會透過Sp1蛋白參與之轉錄機制來調控MCT4蛋白之大量表現,且此現象即使在一般正常氧分壓環境仍可觀察到,因此其對MCT4中和抗體的敏感性較高。 根據目前之實驗結果數據,此兩種藥物具有極大的潛能進行後之藥物發展。但較差的水溶解性及不適當的免疫球蛋白種型可能會是造成日後發展瓶頸的兩大原因。因此,如何針對此兩大問題進行適當的解決及改善勢必是影響此兩種藥物後續能否成功發展成為臨床抗癌藥物的關鍵。慶幸的是,目前在這些藥物開發的領域都有許多新穎的技術及方法被研發出來。因此我們深信,藉由不同領域人員及技術的合作幫忙,GRC0321及MCT4中和抗體必定能在將來發展成為臨床抗癌藥物,提供廣大的肺癌病人族群更多的治療選擇與幫助。 | zh_TW |
dc.description.abstract | Lung cancer is the leading cause of the cancer-related death in the world. Though many improvements in medical and surgical therapies has been done, the advancement in lung cancer mortality remains unsatisfactory. Drug resistance and serious side effects are two important reasons to limit the efficacy and safety of the therapeutic agents targeting lung cancer cells. However, with the introduction of precision medicine, more and more promising diagnostic markers and therapeutic targets have been identified in lung cancer cells recently.
In this dissertation, we adopted two strategies, inclusive of randomizing drug screening and mechanism-based drug design, and successfully identified katanin and Monocarboxylate transporter 4 (MCT4) with corresponding therapeutic agents, GRC0321 and MCT4 neutralizing antibody, for anti-lung cancer treatment. We demonstrated the excellent anti-cancer effects and broad therapeutic windows of these two drugs in the in vitro and in vivo models. Besides, the detail mechanisms of the drugs and the expression regulations of the drug targets in lung cancer cells were also investigated. GRC0321, a small compound, destructed the microtubule structure of lung cancer cells by targeting katanin protein and caused a caspase-9 mediated cancer cell apoptosis through prolonging G2/M cell cycle arrest. On the other hand, the MCT4 neutralizing antibody inhibited the proliferation of glycolysis-dependent subtype of lung cancer cells by blocking the export of excess lactate in the cancer cells. This blockage could reduce the intracellular pH level and increase reactive oxygen species (ROS) production and further activate caspase-9 mediated cancer cell apoptosis. The MCT4 neutralizing therapy revealed excellent effects especially on the MCT4-overexpressed lung cancer cells. To explore the detail mechanisms, we found that this MCT4-overexpressed lung cancer cells had higher dependency on the glycolysis and would express more MCT4 on their cell membranes through a Sp1-mediated transcriptional regulation even in a normoxia condition. Though all the wonderful experimental results of these two drugs make them deserve further development, poor solubility and improper immunoglobulin isotypes are the two major issues encountered and need to be solved in the near future. Fortunately, more and more progresses have been made in these fields which makes us strongly believe that the two drugs could be developed successfully and become clinical therapies to help the patients with lung cancer. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T03:00:05Z (GMT). No. of bitstreams: 1 ntu-106-D00456003-1.pdf: 10913825 bytes, checksum: 023aa4af1391fcb1983ba0576ada8504 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | Contents
中文摘要…………………………………………………………...……... i Abstract…......……………………….…………………….………...….... iii Chapter 1 GENERAL BACKGROUND…………………………………..1 1.1 Non-Small Cell Lung Cancer and Current Treatment ………….2 1.2 Molecular Targeted Therapy for Non-Small Cell Lung Cancer...4 1.3 The Hallmarks of Cancer and Potential Targets for Molecular Therapy……………………………………………………….....7 1.4 Purposes and Aims of this study……………………………….10 Chapter 2 THE EFFECTS AND MECHANISMS OF GRC0321 AS AN ANTI- CANCER DRUG FOR NSCLC…………...…….……………......11 2.1 Introduction………………………………………………….....12 2.2 Materials and Methods…………………………………………14 2.3 Results……………………………………………………….....20 2.4 Discussion……………………………………………………...31 Chapter 3 THE EFFECTS AND MECHANISMS OF TARGETING MONOCARBOXYLATE TRANSPORTER 4 IN NSCLC CELLS …..……………………………………………………………......61 3.1 Introduction…………………………………………………......62 3.2 Materials and Methods………………………………………….64 3.3 Results…………………………………………………………..72 3.4 Discussion……………………………………………………….81 Chapter 4 CONCLUSION AND FUTURE WORKS……………….…..117 References……………………………………………………….……....121 Appendix………………………………………………………………...137 | |
dc.language.iso | en | |
dc.title | 非小細胞肺癌之新藥開發與相關藥物作用標的之研究–
以GRC0321及Monocarboxylate transporter 4為例 | zh_TW |
dc.title | Identify Novel Drug and Related Therapeutic Target in Non-Small Cell Lung Cancer - in terms of GRC0321 and Monocarboxylate transporter 4 | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 李德章,洪澤民,潘思樺 | |
dc.subject.keyword | 肺癌,細胞微管,katanin蛋白,糖解作用,MCT4蛋白, | zh_TW |
dc.subject.keyword | lung cancer,microtubule,katanin,glycolysis,MCT4, | en |
dc.relation.page | 150 | |
dc.identifier.doi | 10.6342/NTU201702037 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2017-07-27 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 轉譯醫學博士學位學程 | zh_TW |
顯示於系所單位: | 轉譯醫學博士學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 10.66 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。